Compare Firy Inc. (FIRY) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Firy Inc. vs 10X Genomics Inc — how do they compare? Firy Inc. trades at $11.97 (market cap $196.97M), while 10X Genomics Inc trades at $79.65 (market cap $9.92B). The key difference: 10X Genomics Inc is far larger — about 50.4× Firy Inc.'s market cap, and Firy Inc. is trading nearer its 52-week high, 10X Genomics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Firy Inc. for 13 Days and 10X Genomics Inc for 92 Days on average.
| FIRY | TXG | |
|---|---|---|
Market Cap | $196.97M | $9.92B |
Volume | 155,239 | 9,372,166 |
Sector | Technology | Health |
52-Week High | $13.10 | $97.74 |
52-Week Low | $2.28 | $11.48 |
Typical Hold Time | 13 Days | 92 Days |
Enterprise Value | $165.57M | $9.44B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FIRY trades at $12.02, down 3.69% on the day, with a bullish technical signal from moving averages but mixed earnings performance. The company shows a high gross margin of 87.76% but negative net income margin of -60.23% and significant cash burn. Recent developments include a $719 million legal victory and board additions, though revenue has declined from $270M in 2022 to $104M in 2025.
The outlook remains challenging with persistent losses and cash burn offset by potential from legal wins. Investment opportunity exists if the company can monetize legal judgments and stabilize operations, but risks include continued operational losses and uncertainty around cash flow sustainability.
10x Genomics (TXG) trades at $77.28, down 4.19% on the day, amid a bearish technical signal. The company reported revenue of $642.82M in 2025, with a net loss of $43.54M, though it has beaten EPS estimates for three consecutive quarters. Recent news highlights the launch of its Atera spatial biology platform and a patent victory, signaling innovation and market strength. Cash flow from operations improved to $136.05M in 2025, indicating better operational efficiency.
The outlook is cautiously optimistic, with strong product demand and improving margins offering upside potential. However, persistent losses, high valuation multiples, and competitive pressures present significant risks. Analyst consensus is mixed, with a $74.30 price target slightly below the current price, reflecting uncertainty about near-term profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Firy Inc.
Firy Inc. operates a mobile gaming platform in the United States, Israel, China, Malta, Hong Kong, Cyprus, and other international markets. The company operates through two segments: Skillz and RZR. Its Skillz platform enables game developers to monetize their content by integrating real-money tournaments, virtual prizes, and social competition features directly into multiplayer games.
Read more on FIRY →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
